Product Information
DASATINIB 100 MG TABLET is a generic product labeled by Aurobindo Pharma Limited, priced at $26.4568 per EA under NDC 59651054630. Its NADAC has been published 65 times since Jul 9, 2025.
FDA first approved this application on Apr 22, 2025. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
100 mg/1
Manufacturer
Aurobindo Pharma LimitedNDC
59651054630
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
DASATINIBApproval Type
Generic (ANDA)
FDA Application
ANDA216547FDA Approved
4/22/2025
TE Code
AB
On Market Since
4/22/2025
Pharmacological Classes
Price Statistics
The NADAC for DASATINIB 100 MG TABLET has been published 65 times since Jul 9, 2025, and over the history we have for it it has declined 86.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $26.4568 per EA |
|---|---|
| All-time high | $191.7363 (Dec 10, 2025) |
| All-time low | $26.1835 (Aug 19, 2026) |
| 52-week high | $191.7363 |
| 52-week low | $26.1835 |
| Median price | $29.9565 |
| Average price | $85.9691 |
| Largest weekly change | -84.2% (Dec 17, 2025) |
| Weeks tracked | 65 |
| Tracking since | Jul 9, 2025 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the DASATINIB market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Aurobindo Pharma Limited manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
DASATINIB market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Kinase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DASATINIB 100 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for DASATINIB 100 MG TABLET, manufactured by Aurobindo Pharma Limited, is $26.4568 per EA (NDC 59651054630), effective Sep 30, 2026.
How has the price of DASATINIB 100 MG TABLET changed over time?
Over the history we have for it, the NADAC for DASATINIB 100 MG TABLET has declined 86.2%. It has been tracked across 65 weekly CMS publications since Jul 9, 2025.
What are the highest and lowest recorded NADAC prices for DASATINIB 100 MG TABLET?
Since Jul 9, 2025, the NADAC for DASATINIB 100 MG TABLET has ranged from a low of $26.1835 (Aug 19, 2026) to a high of $191.7363 (Dec 10, 2025), with a median of $29.9565 per EA.
Are there cheaper alternatives to DASATINIB 100 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of DASATINIB 100 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures DASATINIB 100 MG TABLET?
DASATINIB 100 MG TABLET (NDC 59651054630) is labeled by Aurobindo Pharma Limited, and CMS classifies it as a generic product.